Home > Boards > US OTC > Delisted > CardioVascular BioTherapeutics (fka CVBT)

<u>How zombie companies like Venturis Therapeutics die</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
walhall Member Profile
Followed By 0
Posts 334
Boards Moderated 1
Alias Born 09/15/16
160x600 placeholder
Blackstone's BioMed to Invest $1.2 Billion in New UK Labs
U.S. real-estate investment company BioMed Realty said Tuesday that it plans to significantly increase its laboratory space in the U.K. after acquiring two sites in the city of Cambridge.
Compass Group Says 4Q Underlying Revenue to Be 86% of Fiscal Year 2019's
AstraZeneca to Build $360 Million Manufacturing Plant in Dublin
EMEA Morning Briefing: Stocks to Rebound as Markets Look Calmer
Top Company News of the Day
Elliott Management Reduces SoftBank Group Stake, New York Post Reports
Verrica Pharma Shares Slide 25% After Company Receives Letter From FDA
FedEx Increasing Shipping Rates Next Year
Air Products Raising N Amer Prices for Liquid and Bulk Industrial Gas Products
Soybeans Slide as Investors Retreat to Safe Havens -- Daily Grain Highlights
Correction to Dow Earnings Headline on July 22
Front Month Nymex Natural Gas Fell 2.35% to Settle at $4.9850 -- Data Talk
Front Month Nymex RBOB Gasoline Fell 2.58% to Settle at $2.1152 -- Data Talk
JPMorgan on Track for Largest Percent Decrease Since June 2020 -- Data Talk
Housing Starts, Existing Home Sales on Tap -- Data Week Ahead Update
Aveo Oncology Shares Drop 7% After Fast Track Designation for Ficlatuzumab
UBS Group Down Over 6%, on Track for Largest Percent Decrease Since June 2020 -- Data Talk
Universal Music Group's Reference Price Is Set at EUR18.5
EURO STOXX 50 Index Ends 2.11% Lower at 4043.63 -- Data Talk
STOXX Europe 50 Index Ends 1.37% Lower at 3473.55 -- Data Talk
CAC 40 Index Ends 1.74% Lower at 6455.81 -- Data Talk
walhall   Thursday, 06/25/20 10:46:52 AM
Re: None
Post # of 3610 
How zombie companies like Venturis Therapeutics die

Venturis Therapeutics (formerly Cardiovascular Biotherapeutics or CVBT) has for all practical purposes been dead since 2008. But like a good zombie company, it has continued onwards pointlessly for another 13 years, trying to give every impression of viability where there is none. Zzzombie….zzzombie….zzzzzzombie…….zzzzzzzzzzzzz.........

But even zombie companies like Venturis Therapeutics eventually die. And that death for Venturis is at hand, now that Venturis has suffered a crushing 7-figure judgment it reportedly can’t pay. Further, Venturis is facing a winning adversary that is rumored to be planning very aggressive collection efforts. Once the final judgment amount is announced by the judge arbitrator, the collection effort is likely to immediately commence.

The only question unclear to me is whether or not Venturis’s death will come from involuntary bankruptcy and liquidation, or if Venturis will file for bankruptcy itself in the onslaught of collection activities and then be liquidated (there is no revenue stream here, so liquidation is certain). One fact is clear to me: Venturis will not be able to pay the judgment. The company has been insolvent for over a decade, and according to a particular insider who left the company and spoke candidly with a shareholder who reached out to him/her, Venturis/CVBT has been out of cash for years (i.e. illiquid) and is unable to advance on anything meaningful or costly (patents are cheap, and in this case, pointless). All the absurd chatter here indicating that Venturis Therapeutics or CVBT has raised $10 million, $150 million, $2 billion, or whatever fictional number suits the moment, based on valuations that exceed Apple’s or whatever nonsense is being spouted, is pure fantasy with a strong alcoholic delusional component. Let's face it, no one is going to invest a dime in a company that's led by an accused crook who's alleged by the U.S. governement to have stolen $14 million from his previous company, and who has repeated accusations of fraud hovering around companies he's been involved with, more than a few of which have ended up in bankruptcy. I'm referring of course to Calvin Wallen III. Venturis has provided zero evidence that any money has come in—-because it didn’t as best anyone can tell. Indeed, CFO Robert Schleizer said at one of the annual shareholder meetings that the company had received a qualified audit from its auditors with a going concern disclaimer. Do you know what that’s called in accounting circles? The death spiral. Companies rarely recover from it. And this one won’t.

So long, farewell, auf wiedersehen, goodbye...

For more information:

And to hear more from a Venturis insider who spilled the beans:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences